TScan Therapeutics Inc (TCRX) News & EventsTCRXTScan Therapeutics Inc

TScan Reports Q2 Revenue of $1.05M, Below Consensus

Reports Q2 revenue $1.05M, consensus $2.5M. "This is a transformative time for TScan with our first pivotal study now enrolling at major transplant centers across the U.S.," said Gavin MacBeath, Chief Executive Officer. "A key priority during the first half of this year was demonstrating the performance of our improved commercial-ready manufacturing process. Data from Cohort C of the ALLOHA trial, generated using this process, reinforces our confidence in both our manufacturing and the clinical potential of TSC-101 as we enter our Phase 3 study. Building on the encouraging efficacy we have observed with TSC-101, we are also expanding our heme program to address additional HLA types, with Phase 1 trials of TSC-102-A01 and TSC-102-A03 expected to begin in the fourth quarter of this year."

TScan Therapeutics Infuses First Patient with TSC-101

TScan Therapeutics announced that the first patient has been infused with TSC-101 in the pivotal Phase 3 ALLOHA-2 trial. The patient, who was enrolled in June, has now received their first infusion of TSC-101 following successful stem cell engraftment. The trial is investigating the efficacy and safety of TSC-101 for the treatment of residual disease to prevent relapse following allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia and myelodysplastic syndromes.

TScan Therapeutics ALLOHA Study Data Update

TScan Therapeutics presented data from Cohort C of the ongoing ALLOHA Phase 1 study, evaluating TSC-101 generated with the commercial-ready manufacturing process, in patients with heme malignancies undergoing allogeneic hematopoietic cell transplantation. Overall, 19 patients were enrolled in Cohort C: approximately 90% manufacturing success rate with commercial-ready process; 14/19 patients went to transplant and received their first infusion of TSC-10; 10/14 patients have received their planned second infusion, and 1/14 patients received a third infusion; 3/19 patients did not proceed to transplant due to clinical reasons. Chimerism data as observed by high sensitivity NGS assay with assay cut-off of 0.2%: 11 of 14 patients achieved complete donor chimerism within approximately 3 weeks of receiving their first infusion of TSC-101 and 2 of the remaining 3 patients are approaching complete donor chimerism. One patient with TP53 mutated AML remained in complete donor chimerism 6 months post-HCT. TSC-101 infusions were generally well-tolerated, safety was consistent with Cohort A, and observed adverse events were consistent with post-HCT adverse events.